The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) is a huge mover today! About 575,783 shares traded hands. Global Blood Therapeutics Inc (NASDAQ:GBT) has risen 0.88% since April 13, 2016 and is uptrending. It has underperformed by 3.05% the S&P500.
The move comes after 6 months negative chart setup for the $771.46 million company. It was reported on Nov, 15 by Barchart.com. We have $18.15 PT which if reached, will make NASDAQ:GBT worth $54.00M less.
Global Blood Therapeutics Inc (NASDAQ:GBT) Ratings Coverage
Out of 4 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Global Blood Therapeutics has been the topic of 7 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. Morgan Stanley initiated Global Blood Therapeutics Inc (NASDAQ:GBT) rating on Tuesday, September 8. Morgan Stanley has “Overweight” rating and $67.0 price target. Goldman Sachs initiated Global Blood Therapeutics Inc (NASDAQ:GBT) rating on Tuesday, September 8. Goldman Sachs has “Neutral” rating and $44.0 price target. The company was maintained on Tuesday, October 25 by Wedbush. The rating was initiated by Wedbush with “Outperform” on Tuesday, September 8. Empire maintained the shares of GBT in a report on Friday, June 17 with “Buy” rating.
According to Zacks Investment Research, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.”
More notable recent Global Blood Therapeutics Inc (NASDAQ:GBT) news were published by: Fool.com which released: “Why Global Blood Therapeutics Inc.’s Shares Are Soaring Today” on October 25, 2016, also Fool.com with their article: “Why Global Blood Therapeutics Inc Shares Are Tanking Today” published on December 07, 2015, Fool.com published: “Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today” on June 10, 2016. More interesting news about Global Blood Therapeutics Inc (NASDAQ:GBT) were released by: Prnewswire.com and their article: “Global Blood Therapeutics Announces Appointment of Jeffrey Farrow as CFO” published on April 04, 2016 as well as Prnewswire.com‘s news article titled: “Global Blood Therapeutics Announces Presentation of New GBT440 Data in Sickle …” with publication date: May 19, 2016.
GBT Company Profile
Global Blood Therapeutics, Inc., incorporated on February 04, 2011, is a clinical-stage biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. The Firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Firm is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). HAE is a rare, genetic disorder characterized by severe and potentially life-threatening systemic inflammation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.